The percentages in the table are based on 78.9.M diluted shares, the count I use for valuation purposes (#msg-49785732); these percentages differ from the ones reported in SEC filings. Shares Stake Novartis 31,324,187 39.7% T Rowe Price 8,101,442† 10.3% JP Sommadossi (CEO) 4,026,004* 5.1% BB/MPM Capital 3,321,534 4.2% GlaxoSmithKline 2,474,527 3.1% †Based on Form 13G filed 5/10/10. *Includes 1.8M vested and non-vested options.
Posted by: DewDiligence Date: Monday, August 16, 2010 12:27:59 AM In reply to: DewDiligence who wrote msg# 101688 Post # of 102897
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.